Acquired Immunodeficiency Syndrome
📧 Sign up to get email alerts when something new happens for Acquired Immunodeficiency Syndrome.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-12-18FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) filed by ViiV Healthcare Company.
-
FDA approval · 2024-11-11FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2023-12-13FDA Approved: APRETUDE — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for APRETUDE (cabotegravir) filed by ViiV Healthcare Company, resulting in an updated labeling/indic…
-
FDA approval · 2023-04-05FDA Approved: LAMIVUDINE AND ZIDOVUDINE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Lamivudine and Zidovudine from Exelan Pharmaceuticals, confirming continued availability of this…
-
FDA approval · 2023-03-28FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA granted a supplemental approval for the emtricitabine and tenofovir disoproxil fumarate product from Quallent Pharmaceuticals Health…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-15FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for NORVIR (ritonavir) from AbbVie, resulting in updated labeling for the product. This action r…
-
FDA approval · 2021-03-19FDA Approved: FOSAMPRENAVIR CALCIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for fosamprenavir calcium from Mylan Pharmaceuticals Inc.
-
FDA approval · 2020-06-18FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2020-06-11FDA Approved: ZIDOVUDINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Zidovudine (AZT) by Aurobindo Pharma Limited. This approval supports a generic Zidovudine produc…
-
FDA approval · 2020-02-10FDA Approved: ZIDOVUDINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Zidovudine from Camber Pharmaceuticals, Inc., updating/expanding its approved use or labelin…
-
FDA approval · 2019-07-01FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's supplemental application for Emtricitabine and Tenofovir Disoproxil Fumarate.
-
FDA approval · 2018-11-15FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
The FDA issued a supplemental approval for Kaletra (lopinavir/ritonavir) submitted by AbbVie.
-
FDA approval · 2018-11-15FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Norvir (ritonavir) submitted by AbbVie. The approval updates the product under the NDA, potentia…
-
FDA approval · 2018-07-24FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Emtricitabine and Tenofovir Disoproxil Fumarate by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2018-04-12FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
The FDA approved a supplemental application for dronabinol submitted by Wellhouse Pharma, LLC.
-
FDA approval · 2018-03-06FDA Approved: MYTESI — Supplemental Application (Napo Pharmaceuticals, Inc.)
FDA approves a supplemental application for Mytesi (crofelemer) submitted by Napo Pharmaceuticals, Inc. This action approves the supplementa…
-
FDA approval · 2017-11-28FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) from ViiV Healthcare Company.
-
FDA approval · 2017-10-13FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
The FDA approved AbbVie’s supplemental application for KALETRA (lopinavir/ritonavir), authorizing changes to the product labeling and/or add…
-
FDA approval · 2017-10-06FDA Approved: NEVIRAPINE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an Original Application for NEVIRAPINE (nevirapine) from Macleods Pharmaceuticals Limited, marking approval of a generic antire…
-
FDA approval · 2017-08-28FDA Approved: DRONABINOL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for dronabinol from Ascend Laboratories, LLC.
-
FDA approval · 2017-04-10FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company. The approval pertains to the supplem…
-
FDA approval · 2017-04-10FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-02-24FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2016-03-10FDA Approved: ETRAVIRINE — Supplemental Application (Patriot Pharmaceuticals)
FDA approved a supplemental application for ETRAVIRINE submitted by Patriot Pharmaceuticals, leading to changes to the drug's labeling and/o…
-
FDA approval · 2016-02-25FDA Approved: TRUVADA — Supplemental Application (Gilead Sciences, Inc)
FDA approved a supplemental application for TRUVADA (emtricitabine and tenofovir disoproxil fumarate) submitted by Gilead Sciences, Inc.